Delving into the Latest Updates on Tamoxifen Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene

+ [18]

Target

ER

Mechanism

ERs antagonists(Estrogen receptors antagonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Estrogen receptor positive breast cancerNoninfiltrating Intraductal CarcinomaBreast Cancer+ [1]

Inactive Indication

Advanced Malignant Solid NeoplasmDementiaEarly Stage Breast Carcinoma+ [6]

Originator Organization

AstraZeneca PLC

Active Organization

Mayne Pharma, Inc.

Daré Bioscience, Inc.

Suzhou First Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

AstraZeneca PLCAstraZeneca Pharmaceuticals LP

Drug Highest PhaseApproved

First Approval Date

US (30 Dec 1977),

Breast Cancer

RegulationOrphan Drug (EU)

Login to view timeline

Structure

Molecular FormulaC32H37NO8

InChIKeyFQZYTYWMLGAPFJ-OQKDUQJOSA-N

CAS Registry54965-24-1

This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (locally advanced) and is unable to be operated on (inoperable). Tamoxifen works by blocking the effects of estrogen in the breast. This may help stop the growth of tumor cells that need estrogen to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving tamoxifen and pegylated liposomal doxorubicin together may work better in treating patients with metastatic or inoperable, locally advanced triple negative breast cancer than giving either of these drugs alone.

Start Date15 Feb 2025

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT06630325 / Not yet recruitingPhase 2IIT

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)

This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy [SMMART])-adaptive clinical treatment [ACT]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drugs may work against a person's cancer or why drugs stop working. These test results are reviewed by a group of physicians and scientists during a SMMART tumor board who then recommend precision therapy.

Start Date01 Feb 2025

Sponsor / Collaborator

OHSU Knight Cancer Institute

[+3]

NCT06671912 / Not yet recruitingPhase 3IIT

LoTam: a Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Start Date15 Nov 2024

Sponsor / Collaborator

Alliance for Clinical Trials in Oncology

[+1]

100 Clinical Results associated with Tamoxifen Citrate

Login to view more data

100 Translational Medicine associated with Tamoxifen Citrate

Login to view more data

100 Patents (Medical) associated with Tamoxifen Citrate

Login to view more data

19,774

Literatures (Medical) associated with Tamoxifen Citrate

Oncotarget

miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer

Article

Author: Park, Jong Hoon ; Lee, Yeon Seon ; Kim, Ye Sol ; Park, Sae Jeong ; Kong, Hyun Kyung

Estrogen receptor-alpha (ERα) is a clinically important therapeutic target for breast cancer. However, tumors that lose ERα are less responsive to anti-estrogens such as tamoxifen. MicroRNAs (miRNAs) are small RNAs that regulate expression of their target gene and dysregulations of miRNA has been identified in many diseases including human cancer. However, only a few miRNAs associated with tamoxifen resistance has been reported. In this study, we found that lymphocyte antigen 6 complex (LY6K), which is a member of the Ly-6/μPAR superfamily and related to breast cancer progression and metastasis, is inversely correlated with ERα expression. We, for the first time, found miRNAs involved in the regulatory molecular mechanism between ERα and LY6K and related to tamoxifen susceptibility in breast cancer. miR-192-5p, induced by LY6K, downregulates ERα directly and induced tamoxifen resistance in ERα-positive breast cancer cells. In addition, re-expression of ERα in ERα-negative breast cancer cells increased miR-500a-3p expression and directly inhibits LY6K expression. Ectopic expression of miR-500a-3p sensitized ERα-negative cells to tamoxifen by increasing apoptosis. Finally, we observed an inverse correlation between LY6K and ERα in primary breast cancer samples. We found that patients with recurrence showed high expression of miR-192-5p after tamoxifen treatments. In addition, expression of miR-500a-3p was significantly correlated to survival outcome. As miRNAs involved in the regulatory mechanism between LY6K and ERα can affect tamoxifen resistance, downregulating miR-192-5p or re-expressing miR-500a-3p could be a potential therapeutic approach for treating tamoxifen resistant patients.

01 Mar 2025·Genes & Diseases

TMEM132E ablation suppresses tumor progression and restores tamoxifen sensitivity by inducing ERα expression in triple-negative breast cancer

Article

Author: Sun, Wenjie ; Duan, Ruonan ; Li, Xi ; Gao, Shang ; Liu, Qiji ; Li, Jiangxia ; Sun, Ping ; Wang, Zekun ; Jin, Yecheng

31 Dec 2024·The Journal of dermatological treatment

The impact of hormones in autoimmune cutaneous diseases

Review

Author: Werth, Adrienne J. ; Werth, Victoria P. ; Lopes Almeida Gomes, Lais ; Thomas, Preethi

INTRODUCTION:

Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and these two skin diseases.

MATERIALS AND METHODS:

We performed an extensive literature search using the PubMed database from July to August 2023. Search terms included 'contraceptives', 'pregnancy', 'hormone replacement', 'tamoxifen', and 'aromatase inhibitors'.

RESULTS AND DISCUSSION:

This comprehensive literature review shows that there remains considerable debate regarding the use of hormonal contraceptives and hormonal replacement therapy in individuals with autoimmune skin conditions. Nonetheless, it is well established that their use is contraindicated in patients with antiphospholipid syndrome or when antiphospholipid antibodies are positive. Individuals experiencing disease flares and uncontrolled symptoms should also avoid these interventions. Pregnancy planning should be timed to coincide with well-managed disease states to minimize obstetric and neonatal complications. Hormonal breast cancer treatment requires close skin monitoring.

CONCLUSION:

Pregnancy, menopause, contraceptive use, hormone replacement therapy, and breast cancer treatment drugs result in substantial shifts in hormone levels. Additionally, hormone levels are altered by aromatase inhibitors and anti-estrogen medications. These fluctuations can modulate mechanisms influencing autoimmune skin abnormalities.

9

News (Medical) associated with Tamoxifen Citrate

16 Dec 2024

·www.drugs.com

Study Supports Tamoxifen for DCIS Early Breast Cancers

MONDAY, Dec. 16, 2024 -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, a new study says. Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS) were 44% to 51% less likely to have their cancer return in that breast, researchers reported last week at the annual San Antonio Breast Cancer Symposium (SABCS). The risk of cancer returning is one of the most important factors that doctors and patients weigh following DCIS surgery, said researcher Dr. Jean Wright , chair of radiation oncology at the University of North Carolina. Until now, it hasn’t been clear whether tamoxifen could help prevent cancer from coming back in this group of patients, Wright said in an SABCS news release. “This finding, in such a robust data set, is clarifying,” Wright said. "Tamoxifen, radiation or both, as well as the omission of any adjuvant therapy, are all reasonable options,” Wright added. “Now, we have more data to help our patients choose among these.” DCIS involves abnormal cells found within a milk duct in the breast. It’s an early, noninvasive form of breast cancer that accounts for about 20% to 25% of all new breast cancer cases in the United States, according to the National Breast Cancer Foundation. Tamoxifen has been used for more than 40 years to treat breast cancers that are fueled by the female hormone estrogen, according to the Susan G. Komen Foundation . It works by blocking estrogen receptors in cancer cells, For this study, researchers combined data from two clinical trials to evaluate outcomes for nearly 900 women treated for low-risk DCIS. About 43% of the women received tamoxifen after undergoing breast-conserving surgery to remove their cancer. Women who received tamoxifen had an 11% risk of cancer recurring in the breast with DCIS, compared to 19% for women who didn’t take the drug, results showed. When adjusted for the size of their DCIS, patients who took tamoxifen were 44% less likely to experience recurrence, results show. Likewise, when adjusted for DCIS grade, the tamoxifen patients were 51% less likely to have their cancer come back. Grade refers to how abnormal cancer cells look under a microscope -- the higher the grade, the faster the cancer is likely to grow and spread. These findings support current guidelines from the National Comprehensive Cancer Network, which advises that women who receive a lumpectomy for DCIS consider tamoxifen after surgery, researchers noted. “The more information we can provide patients about the impact of specific treatments, the more we can empower patients to make choices that are right for them,” Wright said in a news release. “I believe that being able to provide clear information to our patients leads to the best care.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultRadiation Therapy

24 Oct 2024

·www.prnewswire.com

Katie Couric Introduces Lost Women of Science's Podcast Finding Dora Richardson, Which Uncovers the Story of the Forgotten Woman Who Developed Tamoxifen, A Groundbreaking Breast Cancer Drug

SAN FRANCISCO, Oct. 24, 2024 /PRNewswire/ -- As part of Breast Cancer Awareness Month, Lost Women of Science is releasing its new two-part podcast, Finding Dora Richardson, with an introduction by Katie Couric, former host of CBS News and the NBC Today Show, and founder of Katie Couric Media. Couric, a breast cancer survivor, was eager to help tell the story of forgotten female chemist Dora Richardson. In the early 1960s Richardson synthesized the compound that came to be known as tamoxifen while she was working at British chemical company International Chemical Industries (ICI). Continue Reading Finding Dora Richardson Katie Couric. Photo: Andrew Eccles. Tamoxifen was first introduced for sale in the 1970s and went on to become a groundbreaking cancer treatment that has saved the lives of hundreds of thousands of women. Part One of Finding Dora Richardson airs today. Listen to Finding Dora Richardson here. Part Two airs on October 31. "To be honest with you, I've never heard of her. In fact, very few people have and there's a reason for that. Her remarkable story has never been told," says Katie Couric about Dora Richardson. Until now. Virtually the only evidence of Dr. Dora Richardson's pivotal role in the development of tamoxifen was her name on the 1965 patent. Through persistent reporting, Lost Women of Science has pieced together Dora's life and her role in developing the groundbreaking breast cancer therapy. We are also thrilled to announce that we found Dora's lost, unpublished History of Nolvadex, as tamoxifen was then called by ICI, which is now part of pharmaceutical company AstraZeneca. "The moment we watched the archivist pull Dora's history from the bottom of a forgotten box, we knew we could tell her story. And what a story it is!" said Katie Hafner, host and co-founder of Lost Women of Science. It's the mission of Lost Women of Science to tell the stories of female scientists who never got the recognition they deserved during their lifetimes. With this podcast, Dr. Dora Richardson, who died in 1998, will now get the credit she is due. This two-part podcast was produced with the generous support of AstraZeneca. About Lost Women of Science: The Lost Women of Science Initiative is a 501(c)3 nonprofit with two overarching and interrelated missions: to tell the story of female scientists who made ground-breaking achievements in their fields, yet remain largely unknown, and to inspire girls and young women to pursue education and careers in STEM. The Initiative's major funders include the Alfred P. Sloan Foundation and the Anne Wojcicki Foundation. Visit our website to sign up for notification of new podcasts. Follow us on Twitter and Instagram: @lostwomenofsci CONTACT: Eowyn Burtner Phone: 415-754-0625, [email protected] or Debora Unger [email protected] Phone +44 7432166622 SOURCE Lost Women of Science Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

27 Aug 2024

·www.prnewswire.com

Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy - TOKYO, Aug. 27, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the HIGHLIGHT 1™ Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy. Breast cancer is the most common cancer in women globally, with approximately 2.3 million new cases in 2022.1 Hot flashes and night sweats, also known as VMS, are recognized as the most prominent side effect of adjuvant endocrine therapies used in the treatment of breast cancer. Approximately 77% of breast cancers can be treated with adjuvant endocrine therapies,2 most commonly tamoxifen and aromatase inhibitors, and up to 97% of breast cancer patients experience hot flashes or night sweats.3 Marci English, Vice President, Head of BioPharma Development, Astellas "VMS can adversely affect quality of life, as well as compliance with treatment, for patients with breast cancer taking adjuvant endocrine therapy. We are excited to get the HIGHLIGHT 1 study underway, as currently there are no approved treatments for moderate to severe VMS that can be used by these patients." About HIGHLIGHT 1 HIGHLIGHT 1 (NCT06440967) is a randomized, placebo-controlled, double-blind, Phase 3 clinical study to assess the efficacy and safety of fezolinetant for the treatment of moderate to severe VMS in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy. Approximately 540 participants are planned to be randomized 1:1 to fezolinetant or placebo at up to 100 sites globally. The four coprimary endpoints are change in the frequency and severity of moderate to severe VMS from baseline to weeks 4 and 12. Patients will be treated for 52 weeks with a final evaluation at 55 weeks. About Fezolinetant Fezolinetant is an investigational oral, nonhormonal medicine in clinical development for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy. The safety and efficacy of fezolinetant have not been established in this patient population. VMS are also known as hot flashes or night sweats. Fezolinetant works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron, helping restore the balance in the brain's temperature control center (the hypothalamus) to reduce the number and intensity of hot flashes and night sweats.4,5,6 There is no guarantee the agent will receive regulatory approval or become commercially available for the uses being investigated. About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at . Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. References 1 World Cancer Research Fund International. Breast cancer statistics. . 2 American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society, Inc. 2022. 3 Fenlon D, Morgan A, Khambaita P, et al. NCRI CSG Breast Cancer Symptom Working Party. Management of hot flushes in UK breast cancer patients: clinician and patient perspectives. J Psychosom Obstet Gynaecol. 2017 Dec;38:276-83. 4 Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905. 5 Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27:382-392. 6 Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderate levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015;156:4214-4225. SOURCE Astellas Pharma Inc.

Phase 2Phase 3

100 Deals associated with Tamoxifen Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00966	Tamoxifen Citrate	L02BA01	DB00675

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Estrogen receptor positive breast cancer	US	Mayne Pharma, Inc.	25 Sep 2018
Noninfiltrating Intraductal Carcinoma	US	Mayne Pharma, Inc.	29 Oct 2005
Breast Cancer	US	AstraZeneca Pharmaceuticals LP	30 Dec 1977

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gynecomastia	Phase 3	IT	AstraZeneca PLC	01 Dec 2003
Prostatic Cancer	Phase 3	IT	AstraZeneca PLC	01 Dec 2003
Hormone receptor positive breast cancer	Phase 3	AT	AstraZeneca PLC	01 Jan 1996
Early Stage Breast Carcinoma	Phase 3	-	AstraZeneca PLC	01 Dec 1990
Vulvovaginal atrophy	Phase 2	AU	Daré Bioscience, Inc.	22 Nov 2021
Dementia	Phase 2	US	AstraZeneca PLC	01 Jan 2007
Dementia	Phase 2	IT	AstraZeneca PLC	01 Jan 2007
Metastatic Neoplasm to the Bladder	Phase 2	US	AstraZeneca PLC	01 Jan 2007
Metastatic Neoplasm to the Bladder	Phase 2	IT	AstraZeneca PLC	01 Jan 2007
Transitional Cell Carcinoma	Phase 2	US	AstraZeneca PLC	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02913430 (CTgov)	Early Phase 1	Metastatic breast cancer	7	Fulvestrant+Palbociclib (Fulvestrant + Palbociclib)	ehiqoiarcy(daftdkhnkr) = pgiilcbrjd uhqzxauajj (sjbgztblbi, ccvylhejlk - domprtmyhm) View more	-	23 Sep 2024
				Tamoxifen+Palbociclib (Tamoxifen + Palbociclib)	ehiqoiarcy(daftdkhnkr) = osgkqeclco uhqzxauajj (sjbgztblbi, xxocfsohad - qewdobsdzu) View more
NCT00072462 (IBIS-II DCIS, CTgov)	Phase 3	Ductal Carcinoma \| Breast Cancer \| Noninfiltrating Intraductal Carcinoma	2,980	anastrozole (Anastrozole)	juifdseqfu(nejwrvmngq) = fqdotovxkk xsowtimqtm (asgqlqaloa, hzyroojmba - grythljzln) View more	-	19 Sep 2024
				tamoxifen citrate (Tamoxifen)	juifdseqfu(nejwrvmngq) = oleqyaujss xsowtimqtm (asgqlqaloa, aldwpsueci - rjfmsxnhbq) View more
Stockholm Tamoxifen 2, 3 and 5 trials (ESMO2024)	Not Applicable	Breast Cancer ER-positive \| HER2-negative \| luminal A ... View more	952	Tamoxifen therapy	hvwvjbvena(jkvvjartsf): HR = 0.58 (95% CI, 0.43 - 0.79)	Positive	16 Sep 2024
				Control
STO-trials (ESMO2024)	Not Applicable	Breast Cancer Adjuvant estrogen receptor (ER)-positive	822	Tamoxifen therapy	eoyzujruys(xeagcooqpf) = ogvrxvchjr kzlnjisrip (qhfvvnccpd )	Positive	16 Sep 2024
				No endocrine therapy (control)	eoyzujruys(xeagcooqpf) = yijyfxcvwy kzlnjisrip (qhfvvnccpd )
UK/ANZ DCIS randomized trial (ESMO2024)	Not Applicable	Ductal Carcinoma Adjuvant ER (clonal) status	755	tamoxifen (No adjuvant treatment)	edhcyowrbp(nukyjndmip): HR = 4.54 (95% CI, 2.27 - 9.06)	Positive	15 Sep 2024
				Radiotherapy
ASCO2024	Not Applicable	Lymphoma	-	Tamoxifen 20mg daily for 5 years	czysqdmnoz(upvmuigfbl) = increased risks for coronary heart disease oyncmtqxap (qczhtdwbtv ) View more	-	24 May 2024
NCT04129216 (CTgov)	Phase 2	Breast Cancer	30	Blueprint+Tamoxifen Citrate (Tamoxifen Arm)	pyjivldlba(nshmtjqgtl) = cxfmcrgdir srifvwilzy (zgsfhthazb, iqrxhpqekw - cvakgowjrx) View more	-	07 May 2024
				Blueprint+Letrozole (Letrozole Arm)	pyjivldlba(nshmtjqgtl) = midlegjwsc srifvwilzy (zgsfhthazb, xodkqiuhto - nlnemdufwe) View more
NCT00295646 (ABCSG-12, CTgov)	Phase 3	Hormone receptor positive breast cancer	1,803	goserelin+zoledronic acid+anastrozole (AZ (Arimidex+Zoledronate))	hlyhcorlqk(pwvfoqpdlj) = bxumkevwyp pgwfiqydil (jouorohdyi, lhnuwgzfdu - frvcffbnjn) View more	-	15 Mar 2024
				goserelin+Tamoxifen+zoledronic acid (TZ (Tamoxifen+Zoledronate))	hlyhcorlqk(pwvfoqpdlj) = fnqwsojbkq pgwfiqydil (jouorohdyi, zdcmkjzmkv - tfcbkxihkl) View more
NCT01674140 (S1207 \| e3, CTgov)	Phase 3	Hormone receptor positive HER2 negative breast cancer	1,939	placebo+letrozole+tamoxifen citrate+exemestane+leuprolide acetate+goserelin acetate+anastrozole (Placebo)	nmqmklniql(lskmsqmipv) = shavevfphe voklsgprkq (acjyigqxcb, thoczdoqwq - tqvdyuurrt) View more	-	20 Dec 2023
				Everolimus (Everolimus)	nmqmklniql(lskmsqmipv) = feptmibitn voklsgprkq (acjyigqxcb, fzwhhwrecb - yclkfhamfk) View more
AASLD2023	Not Applicable	Breast Cancer	233	No hormone therapy	bgamveiunt(zgemlnpwav) = wfitsujjzl wucgollyyu (aethgwvzhf ) View more	-	10 Nov 2023
				Anastrozole	bgamveiunt(zgemlnpwav) = aezdlxqisc wucgollyyu (aethgwvzhf ) View more